Chemotherapy of hematological malignancies in patients with COVID-19
In the era of COVID-19, the chemotherapy of patients with hematological malignancies has become the cornerstone in hematology. Secondary immunodeficiency as a result of hemoblastosis, predisposes to a more severe course of coronavirus infection, and specific antitumor treatment only exacerbates pati...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2022-04-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/543 |
| _version_ | 1797855459126804480 |
|---|---|
| author | T. S. Chudnova E. A. Baryakh M. S. Litvinenko T. N. Tolstykh O. L. Kochneva E. Y. Grishina E. N. Misyurina K. V. Yatskov E. I. Zhelnova Y. Y. Polyakov K. V. Kaluzhskaya |
| author_facet | T. S. Chudnova E. A. Baryakh M. S. Litvinenko T. N. Tolstykh O. L. Kochneva E. Y. Grishina E. N. Misyurina K. V. Yatskov E. I. Zhelnova Y. Y. Polyakov K. V. Kaluzhskaya |
| author_sort | T. S. Chudnova |
| collection | DOAJ |
| description | In the era of COVID-19, the chemotherapy of patients with hematological malignancies has become the cornerstone in hematology. Secondary immunodeficiency as a result of hemoblastosis, predisposes to a more severe course of coronavirus infection, and specific antitumor treatment only exacerbates patients immunodeficiency. Thus, there is a problem of conducting chemotherapy during the COVID-19 pandemic. At the moment, there are no unified recommendations for risk assessment and choice of treatment for patients with oncohematological diseases and concomitant coronavirus infection. In this article, we present a series of clinical cases of patients with hematological malignancies diagnosed with coronavirus infection at the onset of a hematological disease or after chemotherapy. Patients with long-term persistent coronavirus infection requiring specific anticancer treatment were allocated to a separate group. We hope that this article will help to set a vector for further research, as well as serve as a clear example of the clinical situations that a hematologist may face during the COVID-19 pandemic. |
| first_indexed | 2024-04-09T20:24:06Z |
| format | Article |
| id | doaj.art-4193169dc7fd4d628f4896e9cce3fcb9 |
| institution | Directory Open Access Journal |
| issn | 1818-8346 2413-4023 |
| language | Russian |
| last_indexed | 2024-04-09T20:24:06Z |
| publishDate | 2022-04-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Онкогематология |
| spelling | doaj.art-4193169dc7fd4d628f4896e9cce3fcb92023-03-30T20:15:14ZrusABV-pressОнкогематология1818-83462413-40232022-04-0117210712010.17650/1818-8346-2022-17-2-107-120442Chemotherapy of hematological malignancies in patients with COVID-19T. S. Chudnova0E. A. Baryakh1M. S. Litvinenko2T. N. Tolstykh3O. L. Kochneva4E. Y. Grishina5E. N. Misyurina6K. V. Yatskov7E. I. Zhelnova8Y. Y. Polyakov9K. V. Kaluzhskaya10City Clinical Hospital No. 52, Moscow Healthcare DepartmentCity Clinical Hospital No. 52, Moscow Healthcare DepartmentCity Clinical Hospital No. 52, Moscow Healthcare DepartmentCity Clinical Hospital No. 52, Moscow Healthcare DepartmentCity Clinical Hospital No. 52, Moscow Healthcare DepartmentCity Clinical Hospital No. 52, Moscow Healthcare DepartmentCity Clinical Hospital No. 52, Moscow Healthcare DepartmentCity Clinical Hospital No. 52, Moscow Healthcare DepartmentCity Clinical Hospital No. 52, Moscow Healthcare DepartmentCity Clinical Hospital No. 52, Moscow Healthcare DepartmentCity Clinical Hospital No. 52, Moscow Healthcare DepartmentIn the era of COVID-19, the chemotherapy of patients with hematological malignancies has become the cornerstone in hematology. Secondary immunodeficiency as a result of hemoblastosis, predisposes to a more severe course of coronavirus infection, and specific antitumor treatment only exacerbates patients immunodeficiency. Thus, there is a problem of conducting chemotherapy during the COVID-19 pandemic. At the moment, there are no unified recommendations for risk assessment and choice of treatment for patients with oncohematological diseases and concomitant coronavirus infection. In this article, we present a series of clinical cases of patients with hematological malignancies diagnosed with coronavirus infection at the onset of a hematological disease or after chemotherapy. Patients with long-term persistent coronavirus infection requiring specific anticancer treatment were allocated to a separate group. We hope that this article will help to set a vector for further research, as well as serve as a clear example of the clinical situations that a hematologist may face during the COVID-19 pandemic.https://oncohematology.abvpress.ru/ongm/article/view/543covid-19chemotherapyacute leukemiahodgkin lymphomaanaplastic large cell lymphomarichter’s syndrome |
| spellingShingle | T. S. Chudnova E. A. Baryakh M. S. Litvinenko T. N. Tolstykh O. L. Kochneva E. Y. Grishina E. N. Misyurina K. V. Yatskov E. I. Zhelnova Y. Y. Polyakov K. V. Kaluzhskaya Chemotherapy of hematological malignancies in patients with COVID-19 Онкогематология covid-19 chemotherapy acute leukemia hodgkin lymphoma anaplastic large cell lymphoma richter’s syndrome |
| title | Chemotherapy of hematological malignancies in patients with COVID-19 |
| title_full | Chemotherapy of hematological malignancies in patients with COVID-19 |
| title_fullStr | Chemotherapy of hematological malignancies in patients with COVID-19 |
| title_full_unstemmed | Chemotherapy of hematological malignancies in patients with COVID-19 |
| title_short | Chemotherapy of hematological malignancies in patients with COVID-19 |
| title_sort | chemotherapy of hematological malignancies in patients with covid 19 |
| topic | covid-19 chemotherapy acute leukemia hodgkin lymphoma anaplastic large cell lymphoma richter’s syndrome |
| url | https://oncohematology.abvpress.ru/ongm/article/view/543 |
| work_keys_str_mv | AT tschudnova chemotherapyofhematologicalmalignanciesinpatientswithcovid19 AT eabaryakh chemotherapyofhematologicalmalignanciesinpatientswithcovid19 AT mslitvinenko chemotherapyofhematologicalmalignanciesinpatientswithcovid19 AT tntolstykh chemotherapyofhematologicalmalignanciesinpatientswithcovid19 AT olkochneva chemotherapyofhematologicalmalignanciesinpatientswithcovid19 AT eygrishina chemotherapyofhematologicalmalignanciesinpatientswithcovid19 AT enmisyurina chemotherapyofhematologicalmalignanciesinpatientswithcovid19 AT kvyatskov chemotherapyofhematologicalmalignanciesinpatientswithcovid19 AT eizhelnova chemotherapyofhematologicalmalignanciesinpatientswithcovid19 AT yypolyakov chemotherapyofhematologicalmalignanciesinpatientswithcovid19 AT kvkaluzhskaya chemotherapyofhematologicalmalignanciesinpatientswithcovid19 |